在JAK2V617F驱动的骨髓增殖性瘤中,SRSF2突变减少了多细胞血症并损害了造血原体功能
Yue Yang1, Salar Abbas1, Mohammad A Sayem1
1Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA.
Blood cancer journal
|November 27, 2023
概括
在骨髓增殖性瘤 (MPN) 中,SRSF2突变与JAK2V617F结合,降低血细胞数量和脏大小. 这项研究表明,SRSF2突变会损害造血干细胞的竞争力,但不会导致骨髓纤维化.
科学领域:
- 血液学 血液学 血液学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 在骨髓增殖性瘤 (MPN),特别是骨髓纤维化 (MF) 中,SRSF2突变经常与JAK2V617F同时发生.
- 在JAK2V617F驱动的MPN病原体中SRSF2突变的特定作用尚未完全理解.
研究的目的:
- 研究在MPN发育中共同表达的SRSF2P95H和JAK2V617F突变的功能后果.
- 阐明在造血干细胞和祖细胞中这些突变之间的相互作用背后的分子机制.
主要方法:
- 创造诱导性Srsf2P95H/+Jak2V617F/+敲进小鼠的产生.
- 血液学参数分析,壮症和骨髓纤维化.
- 对造血干细胞/原始细胞竞争力和分子信号通路 (TGF-β,S100A8/A9) 的评估.
主要成果:
- 同时表达Srsf2P95H和Jak2V617F减少了红细胞,中性粒细胞和血小板的数量.
- 在复合突变小鼠中,脊髓巨变减弱,骨髓纤维化没有被诱导.
- Srsf2P95H降低了Jak2V617F突变造血干细胞/原始细胞的竞争力,降低了TGF-β水平,并增加了S100A8/A9表达.
结论:
- 同时发生的SRSF2P95H和JAK2V617F突变会损害红细胞形成和造血干细胞功能.
- 这些突变不会促进骨髓纤维化,但会改变特定的分子途径,包括S100A9介导的红细胞参数的影响.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Rous Sarcoma Virus (RSV) and Cancer
5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.1K
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K


